Begin main content

Radioimmunotherapy Using 131-Iodine-8H9 for the Treatment of Central Nervous System Neoplastic Tumours: Clinical Effectiveness and Guidelines

Last updated: September 20, 2018
Project Number: RA0967-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Reference List
Result type: Report

Question

  1. What is the clinical effectiveness of radioimmunotherapy using 131-Iodine-8H9 radiolabeled antibody conjugate for the treatment of central nervous system neoplastic tumours?
  2. What are the evidence-based guidelines associated with the use of 131-Iodine-8H9 radiolabeled antibody conjugate for the treatment of central nervous system neoplastic tumours?

Key Message

No evidence was identified regarding the clinical effectiveness of radioimmunotherapy using 131-Iodine-8H9 radiolabeled antibody conjugate for the treatment of central nervous system neoplastic tumours. No evidence-based guidelines were identified.